Sterigenics rebrands, ups E&L services with Toxikon Europe buy

Under the agreement, contract sterilisation services provider Sotera Health will purchase preclinical contract research organisation (CRO) Toxikon Europe – a division of Toxikon Corporation – in a deal that incorporates all staff and a Belgian facility.

“Toxikon Europe NV has approximately 100 employees and has a state-of-the-art laboratory at their headquarters in Leuven, Belgium, all of which will become part of our Nelson Labs business unit,” ​a Sotera Health spokesperson told us.

The deal also covers a long-term supply agreement under which Nelson Labs will outsource in-vivo ​biocompatibility services to Toxikon USA.

“Nelson Labs will now offer Toxikon Europe’s leading extractables and leachables (E&L) capabilities to its customers around the world and in kind, offer Nelson Labs leading microbiological services to Toxikon Europe’s customers,” ​Sotera Health added.

The Sotera Health spokesperson told us Nelson Labs customers had requested E&L services.

“E&L services are becoming more and more important for our customers and regulatory authorities like FDA ​[the US Food and Drug Administration] in testing medical devices and pharmaceutical products.”​

Sotera Health expects the acquisition to attract new business, said the firm.

“This acquisition expands the breadth of our laboratory capabilities specifically in extractables and leachables and analytical chemistry,” ​the spokesperson said.

“E&L and analytical chemistry capabilities are critical to the pharmaceutical industry and will allow us to better serve our current pharma customers and attract greater pharma business,” ​she added.

The firms did not disclose financial terms of the deal.